Merida Biosciences

Series-A Acquired by Eli Lilly
meridabio.com Biotech & Healthcare Cambridge, United States Founded 2022 11-50
Total Funding $120M
Latest Round $120M Series-A
Last Announced May 7, 2025
Investors 5 Backers
Decision Makers 6 Verified

About Merida Biosciences

Merida Biosciences develops precision treatments for autoimmune diseases. The company uses a protein engineering platform to create Fc therapeutics. These therapeutics aim to selectively bind to specific antibodies.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Cambridge, United States
Year Founded 2022
Team Size 11-50
Corporate Status Acquired by Eli Lilly
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website meridabio.com
Domain Registered Date Jan 29, 2024

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

3 Events
  1. Capital Raise

    Raised $120,000,000 · Series-A

    startupintros.com

  2. Milestone

    Website domain registered

    meridabio.com

  3. Milestone

    Company founded

    Cambridge, United States

Investors & Backers

5
Bain Capital Life Sciences
Biotechnology Value Fund
GV
Perceptive Advisors
Third Rock Ventures

Funding History

1 Round
Series-A · May 7, 2025
$120,000,000 startupintros.com

Founders & Leadership

3

Dario Gutierrez

Founder & Chief Scientific Officer

Work email & phone locked Unlock →

Mark Shlomchik

Co-founder

Work email & phone locked Unlock →

Pierre Bruhns

Co-founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts